ImmunityBio, Inc. (IBRX) Tops Q4 EPS by 8c

ImmunityBio, Inc. (NASDAQ: IBRX) reported Q4 EPS of ($0.09), $0.08 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $7.2 million versus the consensus estimate of $6.16 million.

For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.

You May Also Be Interested In

• Chevron signed an agreement with Iraq's Basra Oil Company to advance commercial negotiations for West Qurna 2
• Surya Oil & Gas faces lawsuit over alleged oral agreement
• Penguin Solutions closes $750M convertible notes offering due 2031